EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nicox's enterprise value is $22.48 Mil.
Nicox's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-16.88 Mil. Therefore, Nicox's EV-to-EBITDA for today is -1.33.
The historical rank and industry rank for Nicox's EV-to-EBITDA or its related term are showing as below:
NICXF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.05 Med: -6.53 Max: -0.44
Current: -1.33
During the past 13 years, the highest EV-to-EBITDA of Nicox was -0.44. The lowest was -43.05. And the median was -6.53.
NICXF's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.1
vs NICXF: -1.33
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-28), Nicox's stock price is $0.44.
Nicox's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.395. Therefore, Nicox's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Nicox EV-to-EBITDA Historical Data
The historical data trend for Nicox's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nicox's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nicox's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nicox's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nicox's EV-to-EBITDA falls into.
Nicox's current Enterprise Value is $22.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nicox's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-16.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nicox (OTCPK:NICXF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nicox's share price for today is $0.44.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nicox's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.395.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Nicox's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NICXF has been successfully added to your 